Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
Date:12/23/2010

SAN FRANCISCO, Dec. 23, 2010 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTC Bulletin Board: PRWP) ("the Company") and maintains its twelve month target price to $2.10. Ross Silver, Principal Analyst at Vista Partners, stated, "DAVANAT®, the Company's lead product candidate, could potentially enhance the efficacy of already approved oncology drugs, such as Avastin®, while also reducing the side effect profile of these drugs. By doing so, patients potentially will live longer and live better and the cost of treatment could be reduced significantly." Mr. Silver goes on to state, "The Company has stated that development of its GR series of compounds, novel carbohydrate compounds intended to treat liver fibrosis, will commence in January 2011. The Company recently entered into a research agreement with the premier liver disease expert in the U.S., Dr. Scott Freidman, at Mt. Sinai Hospital in New York.  Liver disease is considerable and according to the American Liver Foundation, more than 25 million Americans are or have been afflicted with liver and biliary diseases."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. We are a Registered Investment Advisor in the States of California and Oregon. Our professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to
'/>"/>

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
2. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
3. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
4. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
5. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
6. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
7. Watson Confirms EVISTA(R) Patent Challenge
8. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
9. Biovista Inc. Named Top Innovator in Life Sciences
10. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
11. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , Sept. 18, 2014 /PRNewswire/ ... Competition for innovation, increasing clinical development costs, new ... the fast-changing environment are important factors driving industry ... clinical trial costs continue to rise due to ... Studies conducted by industry think tanks suggest each ...
(Date:9/18/2014)... -- Decision Resources Group finds that Regeneron,s Eylea, the most ... wet AMD, is equally likely to be covered on ... is the standard of care for wet AMD. Of ... not identify a clear clinical or economic advantage with ... be listed on tier 1 or 2 on Medicare ...
(Date:9/18/2014)... 18, 2014  Zacks.com announces the list of stocks ... Equity Research analysts discuss the latest news and events ... in the blog include the Avanir Pharmaceuticals (Nasdaq: AVNR ... - Free Report ), Orexigen (Nasdaq: OREX - ... Report ) and Gilead (Nasdaq: GILD - Free ...
Breaking Medicine Technology:Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... Calif., Nov. 8, 2011 ICU Medical, Inc. (NASDAQ: ... presented this past weekend at the 36th annual meeting ... Anaheim, CA has shown that the company,s ChemoClave® closed ... and patients safe from accidental exposure to hazardous drugs ...
... Nov. 8, 2011 Boston Scientific Corporation (NYSE: ... PLATINUM Long Lesion trial, demonstrating excellent outcomes for the ... patients with long coronary lesions.  Results were presented today ... in La Jolla, California, and Co-Principal Investigator of the ...
Cached Medicine Technology:Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs 2Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs 3Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs 4Boston Scientific's PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions 2Boston Scientific's PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions 3Boston Scientific's PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions 4
(Date:9/19/2014)... (PRWEB) September 19, 2014 Atlantic Information ... the authoritative AIS’s Directory of Health Plans — is ... Trends and Data: 2014-2015. The latest edition of the ... re-shaping the health care industry. , With valuable ... issues — from benefit design and management strategies to ...
(Date:9/19/2014)... Internationally acclaimed prosthodontist and presenter Dr. ... conference tomorrow. , Dr. Jivraj, founder of a ... Dental Art Institute, will speak about All-on-4™ dental ... Aspects of Graft Less Solutions.” He is speaking at ... Landmark Hotel & Conference Centre in Vancouver, British Columbia, ...
(Date:9/19/2014)... Germany (PRWEB) September 19, 2014 ... that its new ND® Infusion Catheter is ... of Frankfurt. , The study commenced on September 4th, ... The use of the new catheter demonstrated a number ... known as stem cells. “We are at the forefront ...
(Date:9/19/2014)... 2014 Cancer researchers in Japan have ... on where mesothelioma develops in the body. Click ... this important research. , Doctors with Nara Medical ... pleural mesothelioma (on the lung lining) and those ... study suggests that the pathway of the genetic abnormality ...
(Date:9/19/2014)... 2014 In their latest article ... home care options, Seniors Guide has published, ... http://www.HomeCareChoice.com - their website for finding ... North Carolina, Ohio, and Indiana. , Seniors Guide ... services offered, training and education, and also inquiring ...
Breaking Medicine News(10 mins):Health News:New Book from Atlantic Information Provides Insights Into Trends in the Health Care Industry 2Health News:Ventura Tooth Replacement and Restoration Expert to Speak at Vancouver Conference Tomorrow About All-on-4™ Procedure 2Health News:Ventura Tooth Replacement and Restoration Expert to Speak at Vancouver Conference Tomorrow About All-on-4™ Procedure 3Health News:Ventura Tooth Replacement and Restoration Expert to Speak at Vancouver Conference Tomorrow About All-on-4™ Procedure 4Health News:Ventura Tooth Replacement and Restoration Expert to Speak at Vancouver Conference Tomorrow About All-on-4™ Procedure 5Health News:First-in-man procedure utilizes a new method of stem cell delivery 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 3Health News:New Study Finds Link Between Genes and Mesothelioma Location, Reports Surviving Mesothelioma 2Health News:Seniors Guide Offers Advice on How to Find the Right Home Health Care Agency 2
... Cholesterol-lowering meds seem to shield against troublesome complication, study ... patients who take cholesterol-lowering statins before cardiac surgery may ... study finds. , Depending on variables such as ... 47 percent of people experience this condition of confusion ...
... mechanics can lead to pain and stiffness , , THURSDAY, Dec. 25 ... back. , To ease the backaches that may have come ... and stretching and straining to put up holiday decorations -- and that ... Association offers a 10-step guide: , Zero ...
... these cells more closely mimic those of humans , , ... found a formula to capture indefinitely the basic embryonic ... cells. , If the findings hold up, scientists ... readily produced, genetically altered strains of rats. As humans ...
... conflicting news reports on the ongoing Baxter Heparin blood thinner controversy. ... of death among several patients, but the agency has also alleged ... patients. , ... Denver, CO (PRWEB) December 25, 2008 ...
... Weber Denture Liner kit is designed to answer questions often ... my loose denture fit better, give me more comfort and ... use of this new always-soft Weber Denture Liner. All ... fit better with this new (Patent Pending) invention. The Weber ...
... at risk for dementia, Parkinsons, researchers say , , WEDNESDAY, ... causes them to kick or cry out during deep sleep ... new Canadian study suggests. , "It,s basically a disorder where ... Dr. Ronald B. Postuma, of McGill University in Montreal. "When ...
Cached Medicine News:Health News:Tips to Ease an Aching Back 2Health News:Scientists May Isolate Stem Cells From Rats, Other Mammals 2Health News:LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers 2Health News:LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers 3Health News:LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers 4Health News:New Product Makes Loose Dentures Fit Better 2Health News:New Product Makes Loose Dentures Fit Better 3Health News:Sleep Disorder Could Signal Neurological Disease 2
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... Control is a bilevel liquid ... performance of the most widely ... A weak positive and a ... monitor the performance of your ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Medicine Products: